Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

HISTORICAL FACTS: 5 | History Defined

Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2022

Upgrades

Benzinga

Centene Lifts FY22 Guidance On Higher Medicaid Premiums; Increases Share Buyback

Ahead of its investor day, Centene Corp (NYSE:CNC) increased its Premium and Service Revenues FY22 guidance range by $2.0 billion to $134.3 billion - $136.3 billion. The company also increased adjusted EPS guidance by $0.15 to $5.55 - $5.70 vs. the consensus of $5.49. The company's 2022 financial guidance has been updated to…

Benzinga

Where Centene Stands With Analysts

Over the past 3 months, 5 analysts have published their opinion on Centene (NYSE:CNC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Britain’s biggest chain of GP surgeries accused of ‘profiteering’

BBC Panorama claims Operose Health uses physician associates, who are cheaper to employ than doctors, to assess patients

The Guardian - UK

Looking Into Centene's Recent Short Interest

Centene's (NYSE:CNC) short percent of float has risen 7.87% since its last report. The company recently reported that it has 7.85 million shares sold short, which is 1.37% of all regular shares that are available for trading.

Benzinga

Here's How Much $1000 Invested In Centene 5 Years Ago Would Be Worth Today

Centene (NYSE:CNC) has outperformed the market over the past 5 years by 5.11% on an annualized basis producing an average annual return of 14.96%. Currently, Centene has a market capitalization of $45.83 billion.

Benzinga

$1000 Invested In Centene 15 Years Ago Would Be Worth This Much

Centene (NYSE:CNC) has outperformed the market over the past 15 years by 12.83% on an annualized basis producing an average annual return of 19.78%. Currently, Centene has a market capitalization of $48.21 billion.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

What 4 Analyst Ratings Have To Say About Centene

Over the past 3 months, 4 analysts have published their opinion on Centene (NYSE:CNC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 26, 2022

Upgrades

Benzinga

Centene Offloads Two Pharmacy Businesses For $2.8B

Centene Corporation (NYSE:CNC) has agreed to sell Magellan Rx to Prime Therapeutics LLC and PANTHERx Rare to a consortium of The Vistria Group, General Atlantic, and Nautic Partners. Centene expects to receive approximately $2.8 billion in aggregate proceeds from the transactions. Magellan Rx is a comprehensive pharmacy solutions organization with specialty drug management, Medicaid administration, and comprehensive pharmacy…

Benzinga

General Motors And 3 Other Stocks Insiders Are Selling

US stock futures traded higher ahead of the much-awaited interest rate decision from the Federal Reserve. Investors, meanwhile, focused on some notable insider trades.

Benzinga

Centene's Return On Capital Employed Overview

According to Benzinga Pro, during Q1, Centene (NYSE:CNC) earned $852.00 million, a 43.68% increase from the preceding quarter. Centene also posted a total of $37.19 billion in sales, a 14.18% increase since Q4.

Benzinga

Centene Posts Street Beating Q1 Earnings, Lifts FY22 Outlook

Centene Corporation (NYSE:CNC) has reported a Q1 FY22 adjusted EPS of $1.83, compared to $1.63 a year ago, beating the consensus estimate of $1.68. Sales increased 24% Y/Y to $37.18 billion, beating the consensus of $34.50 billion. Health Benefits Ratio of 87.3%, up from 86.8% a year ago, due to a return…

Benzinga

Recap: Centene Q1 Earnings

Centene (NYSE:CNC) reported its Q1 earnings results on Tuesday, April 26, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Better Buy for 2022: Clover Health vs. Centene

The COVID-19 pandemic has been a blessing for the healthcare plan industry due to increased healthcare spending. In addition, with the rising healthcare needs of an aging population, the industry’s prospects look bright. Clover Health Investments, Corp. (CLOV) and Centene (CNC) should benefit from this trend. But which of these…

Benzinga

Analyst Ratings For Centene

Over the past 3 months, 9 analysts have published their opinion on Centene (NYSE:CNC) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Centene Shares Jump On Better Than Expected Q4 Earnings, Reaffirms FY22 Guidance

Centene Corporation (NYSE: CNC) has reported Q4 adjusted EPS of $1.01,

Benzinga

Recap: Centene Q4 Earnings

Centene (NYSE:CNC) reported its Q4 earnings results on Tuesday, February 8, 2022 at 06:00 AM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100's of premium titles.
One news app.

Wales Online

Campaigners await High Court ruling over US-backed takeover of GP practices

NHS England faces a legal challenge against a decision to approve a 'change in control' of primary care provider AT Medics

The Guardian - UK

US healthcare giant’s takeover of GP practices lands in high court

Judicial review hearing could overturn Centene takeover branded by opponents as ‘NHS privatisation by stealth’

Benzinga

5 Stocks Insiders Are Selling: Accenture, Centene And More

French CAC 40 Index gained around 1% this morning, partially recovering from previous session’s 4% plunge, as investors await the policy decision from the Federal Reserve tomorrow. Investors, meanwhile, focused on some notable insider trades.

1 2 3 4 5

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.